MARKET

RPRX

RPRX

Royalty Pharma plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

45.41
-0.07
-0.15%
After Hours: 45.63 +0.22 +0.48% 17:10 08/14 EDT
OPEN
45.11
PREV CLOSE
45.48
HIGH
45.97
LOW
45.00
VOLUME
599.32K
TURNOVER
--
52 WEEK HIGH
56.50
52 WEEK LOW
39.90
MARKET CAP
27.04B
P/E (TTM)
14.34
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RPRX stock price target is 52.29 with a high estimate of 56.00 and a low estimate of 47.00.

EPS

RPRX News

More
Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million
\- Biohaven will receive up to $250 million to fund zavegepant’s development in migraine and non-migraine indications \- Royalty Pharma to acquire up to a 3% royalty for zavegepant, a 0.4% royalty of Nurtec™ ODT and success-based milestone payments \- Royalty
GlobeNewswire · 08/07 13:40
Royalty Pharma Appoints Henry A. Fernandez and Ted W. Love, M.D. to the Company’s Board of Directors
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced the appointments of Henry A. Fernandez and Ted W. Love, M.D. to the company's Board of Directors, effective immediately. Mr. Fernandez is Chairman and Chief Executive Off
GlobeNewswire · 08/03 20:15
Vanguard Health Care Fund Adds 3 Stocks to Portfolio
GuruFocus News · 07/31 04:00
Royalty Pharma to Announce Second-Quarter 2020 Financial Results on August 12
NEW YORK, July 20, 2020 -- Royalty Pharma (NASDAQ: RPRX) today announced that it will report its second quarter 2020 financial results on Wednesday, August 12, 2020, before the.
GlobeNewswire · 07/20 20:15
Royalty Pharma Acquires Royalty Interest in Risdiplam From PTC Therapeutics
NEW YORK, July 20, 2020 -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. (Nasdaq: PTCT) to acquire a portion of PTC’s royalty.
GlobeNewswire · 07/20 11:45
Keep an Eye on Royalty Pharma Stock, 2020s Biggest IPO
InvestorPlace · 07/02 18:02
Dun & Bradstreet Trades Higher After IPO Raised $1.7 Billion
Bloomberg · 07/01 18:48
New Ventures Portfolio Company, ADC Therapeutics, Completes $267 Million IPO
PR Newswire · 06/30 15:40

Industry

Pharmaceuticals
-0.37%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Symbol
Price
%Change

About RPRX

Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in approximately 45 commercial products and four development-stage product candidates.
More

Webull offers kinds of Royalty Pharma plc stock information, including NASDAQ:RPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RPRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RPRX stock methods without spending real money on the virtual paper trading platform.